Silvia Novello Celebrates the Team Behind Italian Sarcoma Research at AIOM 2026
Silvia Novello/LinkedIn

Silvia Novello Celebrates the Team Behind Italian Sarcoma Research at AIOM 2026

Silvia Novello, Professor of Medical Oncology and Medical Director at Università di Torino, shared on LinkedIn:

“Congratulations to Alessandra Merlini, who today delivered the Venturini Lecture – a prestigious honor during at the annual AIOM event.

Congratulations to the Italian Sarcoma Group on this achievement, and many thanks to Dr. Grignani and Prof. Lorenzo D’Ambrosio for their support – not only of the study TOMAS2 itself, but also of Alessandra in reaching this wonderful milestone.

Silvia Novello Celebrates the Team Behind Italian Sarcoma Research at AIOM 2026

Thanks also to the Gilardi Laboratory (Department of Oncology, University of Turin), which hosted many of the study’s translational analyses and will be the site for future developments too.”

About Italian Sarcoma Group

The Italian Sarcoma Group (ISG) is a non-profit scientific organization dedicated to advancing research and improving care for patients with sarcomas.

Its main activities include:

  • Clinical Research: Coordinating clinical trials focused on sarcomas.
  • Research Collaboration: Bringing together oncologists, surgeons, pathologists, and researchers.
  • Treatment Development: Supporting new approaches to sarcoma diagnosis and treatment.
  • Education: Promoting scientific exchange and professional training.
  • Patient Care: Improving the quality of care for people with bone and soft tissue sarcomas.

About AIOM

AIOM is Italy’s leading scientific association for medical oncology professionals.

AIOM focuses on:

  • Research: Promoting advances in cancer research.
  • Clinical Guidelines: Developing recommendations for cancer diagnosis and treatment.
  • Education: Supporting medical training and professional development.
  • Scientific Events: Organizing annual meetings and oncology conferences.
  • Patient Care: Promoting improvements in cancer prevention and treatment.

You may also be interested in:

Andrea Pretta: Addressing Treatment Personalization Beyond First-Line Therapy in Metastatic Colorectal Cancer at AIOM 2026